data + articles · 2 listed
newest 2004spec sheet10 rows
Aloracetam is an experimental nootropic compound that was investigated as a potential treatment for cognitive impairment, most notably Alzheimer's disease. It is often grouped with the racetam family of cognition agents, though its structure departs from the classic 2-pyrrolidinone racetams. The compound was never brought to market and holds no regulatory approval in any major jurisdiction [1][2].
- Boosted acetylcholine
- Enhanced AMPA signaling
- Sharper memory
- Clearer focus
- Cognitive support
Overview
Aloracetam is a synthetic small-molecule nootropic with the molecular formula C11H16N2O2. It is commonly listed alongside the racetams, a class of compounds studied for effects on memory and cognition, although it lacks the pyrrolidinone ring that defines the classic members of that family. For that reason it is best described as a racetam-adjacent experimental agent rather than a canonical racetam.
The compound emerged from pharmaceutical research aimed at neurodegenerative and cognitive disorders. It appears in industry compilations of agents under investigation for neurodegenerative diseases published in the mid-2000s, surveys that tracked candidate drugs moving through preclinical and clinical pipelines [1][2]. Development was ultimately halted, and aloracetam was never approved or marketed [1].
Reported interest centered on cognition-related indications, in particular Alzheimer's disease, reflecting the broader effort of that period to find agents able to slow cognitive decline or improve memory [1]. Published clinical evidence in humans is essentially absent, and the compound did not advance to routine therapeutic use [2].
The mechanism of action of aloracetam has not been well characterized in the public literature, and it does not have an established pharmacological target of the kind documented for better-studied nootropics. This lack of detailed data reflects how early its development ended.
Aloracetam is not an approved medicine and is unscheduled in the United States. It is not a component of standard pharmaceuticals and has no recognized medical formulation; any material circulating outside research settings would be a non-standardized chemical rather than a regulated drug product [1][2].
Mechanism
Aloracetam's mechanism of action is not firmly established in the published literature. It has been discussed within the racetam and category, a group historically associated with modulation of cholinergic signaling and of receptors such as the subtype, but specific, well-documented target data for aloracetam itself are lacking [1]. Because development did not progress to detailed human pharmacology, its effects in people were never characterized in the way that marketed cognitive agents have been [2].
receptor fingerprint
enhances (proposed)
receptorspositive modulator (proposed)
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Aloracetam never made it to market or approval; it stayed an investigational compound. There's no safety profile, no dosing range, and no clinical guidance out there. It's unscheduled in most places (not a controlled substance) but also not approved for people anywhere, and there's no contraindication or interaction data from trials. With basically no human dosing or safety info to lean on, treat it as pure research territory.
Subjective profileweighing the evidence above
Nothing here to buy. The tidy benefit list is borrowed from the racetam category rather than measured on aloracetam itself, and there is no human dosing, safety or efficacy data at all. The better-studied racetams are where attention belongs.
Resources
This entry is here for reference.
Research
- 1.List of drugs in development for neurodegenerative diseases
- 2.List of drugs in development for neurodegenerative diseases. Update June 2004
2 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is Aloracetam used for?
It is a very obscure racetam-family compound that was explored for Alzheimer's and cognition.
How does Aloracetam work?
It is thought to influence acetylcholine and AMPA signaling, though the mechanism is not well established.
Is Aloracetam well-researched?
Human data is essentially nonexistent, making it highly experimental.
What are the main side effects?
With almost no data, side effects are unknown; racetam-like effects such as headache are plausible.
Limitations of the evidence
- Not an approved or standardized medicine
Notes and cautions
- Human safety data are essentially absent
- No established side-effect profile
- Effects in people were never formally characterized